Literature DB >> 11285337

The clearance and metabolism of biotin administered intravenously to pigs in tracer and physiologic amounts is much more rapid than previously appreciated.

K S Wang1, G L Kearns, D M Mock.   

Abstract

Understanding of biotin pharmacokinetics and regulation of metabolism is essential for the determination of the biotin requirement for humans. Using Landrace-Cambrough pigs as a model, we initially demonstrated that biotin binding to protein accounts for only a small percentage of the total biotin in plasma. A physiologic amount of [14C]biotin was administered intravenously to three pigs; nine blood samples were collected over 48 h. Plasma concentrations of 14C-labeled metabolites were negligible for the first 2 h after biotin infusion. Disappearance curves of total 14C and of [14C]biotin were similar; both fit a triexponential function consistent with a three-compartment, open model. To characterize the rapid early phase of disappearance more precisely, a physiologic amount of [14C]biotin was administered intravenously to five pigs; eight blood samples were collected over the first hour and 16 total samples over 48 h. Again a triexponential function provided an excellent fit. The mean half-life values (+/- 1 SD) for the three phases were 0.11 +/- 0.07, 1.43 +/- 0.42 and 22 +/- 4 h. The [14C]biotin accumulated primarily in the liver, kidney and muscle. When administered intravenously at tracer doses to three pigs, [3H]biotin exhibited similar early pharmacokinetics; however, substantial quantities of a 3H-labeled metabolite appeared after 1 h. These studies provide evidence that egress of biotin from plasma is more rapid than previously appreciated. The slower second and third phases may represent transport into the cytosol, biotransformation into intermediates and covalent binding to intracellular proteins. Similar pharmacokinetics are likely to be seen in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11285337     DOI: 10.1093/jn/131.4.1271

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  5 in total

1.  HIGH-DOSE BIOTIN TREATMENT FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS MAY INTERFERE WITH THYROID ASSAYS.

Authors:  Alissa Minkovsky; Mark N Lee; Mitra Dowlatshahi; Trevor E Angell; Lilian S Mahrokhian; Athena K Petrides; Stacy E F Melanson; Ellen Marqusee; Whitney W Woodmansee
Journal:  AACE Clin Case Rep       Date:  2016

2.  Biotin dependency due to a defect in biotin transport.

Authors:  Rebecca Mardach; Janos Zempleni; Barry Wolf; Martin J Cannon; Michael L Jennings; Sally Cress; Jane Boylan; Susan Roth; Stephen Cederbaum; Donald M Mock
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

Review 3.  Biochemical Testing in Thyroid Disorders.

Authors:  Nazanene H Esfandiari; Maria Papaleontiou
Journal:  Endocrinol Metab Clin North Am       Date:  2017-06-08       Impact factor: 4.741

4.  Vitamin H-regulated transgene expression in mammalian cells.

Authors:  Wilfried Weber; William Bacchus; Marie Daoud-El Baba; Martin Fussenegger
Journal:  Nucleic Acids Res       Date:  2007-09-07       Impact factor: 16.971

5.  Imaging Biotin Trafficking In Vivo with Positron Emission Tomography.

Authors:  Salvatore Bongarzone; Teresa Sementa; Joel Dunn; Jayanta Bordoloi; Kavitha Sunassee; Philip J Blower; Antony Gee
Journal:  J Med Chem       Date:  2020-07-24       Impact factor: 7.446

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.